Navigation Links
Autism Research Study Announced By Children's Health Council
Date:3/16/2010

Dr. Glen Elliott of Children’s Health Council leads clinical research for local patients

Palo Alto, CA (PRWEB) March 16, 2010 -- Autism is an exceptionally complex illness. Autism is a developmental disorder with impairments in social interaction and communication, in addition to restricted, repetitive behaviors. Once considered quite rare, 1 in every 150 children in the United States is now diagnosed with the illness, making it a common developmental disability.

Diagnosis of Autism typically occurs at about 3 years of age. The treatment of the condition is complex, as there is no single known cause or cure. Early childhood is the period during which the symptoms of Autism are clearly observable and children are experiencing rapid developmental changes. Researchers continue to look for more effective behavioral, educational and medical treatments to improve the lives of children with Autism. Therefore, a key to overcoming some of the challenges associated with the condition is early diagnosis and intervention.

A clinical research study is now underway in the Bay Area for children between the ages of 3 and 6 with Autistic Disorder. The goal of the study is to evaluate the safety and effectiveness of an investigational medication for children with this condition.

Dr. Glen Elliott of Children’s Health Council (CHC) is conducting this clinical research study. CHC believes all children deserve the opportunity to reach their full emotional, educational and developmental potential. CHC seeks participants for this clinical study, based on the following: the children must be at least 3 years old and less than 7 years old; candidates for the study must meet the criteria for Autistic Disorder; and, she or he must have an IQ or developmental quotient (DQ) of at least 50.

Parents must give informed consent for their child to participate in this clinical research study, and must also be willing and able to comply with all study requirements. All clinical study-related care will be provided at no cost, including physical exams, psychological testing, and study medication. Compensation may be available to eligible parents or guardians. Health insurance is not required to participate.

If your child or a child you know has Autism, additional information about this clinical research study and how to participate is available at (800) 314-2597 and at www.chcautism.com.

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3729964.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Research may unlock mystery of autisms origin in the brain
2. The Philadelphia Walk Now for Autism Expected to Draw 10,000 Walkers and Raise $1 Million to Help Find Answers About the Nations Fastest-Growing Developmental Disorder
3. Rain Man mice provide model for autism
4. Houston Texans Star Players Ahman Green and Matt Schaub Help Easter Seals, Avondale House and Local Families Tackle Autism
5. Study shows autism symptoms can improve into adulthood
6. Brain Imaging Expert Recruited to Study Autism at The Childrens Hospital of Philadelphia
7. USC granted $8.4 million for autism research
8. Autism Speaks Applauds Supreme Court Decision Upholding Families Right to Challenge IEPs Without First Trying Out School District Proposed Placement
9. Reliant Energy, Houston Texans Ahman Green and Matt Schaub Team to Hold News Conference, Book Signing to Raise Awareness about Autism
10. Jenny McCarthy Featured at National Autism Conference in Atlanta, November 9
11. San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research from Guardian’s ... face in trying to balance both short-term and long-term benefits demands. Are ... the growing complexity, companies are finding that the short-term strategies used to control ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
(Date:3/29/2017)... ... 29, 2017 , ... AvePoint , the Microsoft Cloud expert, is pleased ... Virginia, located at the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with ... S. Northam and Mayor of Richmond Levar M. Stoney. , Founded in 2001, AvePoint ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the first technology to directly address the resolution to globally reduce the harmful ... a patented compound of FDA and TTB approved ingredients that when infused into ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017 Varian Medical Systems (NYSE: ... for the second quarter of fiscal year 2017 following the ... news release will be followed by a teleconference available to ... and a link to the conference call webcast will be ... access the teleconference call and replay: ...
(Date:3/29/2017)... , March 29, 2017   Royal Philips ... in health technology, and PathAI, a company that ... with the aim to develop solutions that improve ... cancer and other diseases. The partnership aims to ... this form of artificial intelligence to be applied ...
(Date:3/29/2017)... TEL AVIV, Israel , March 29, 2017 ... license agreement in which Exeltis will obtain exclusive marketing rights for ... ... is an age-appropriate drug targeted to treat sleep disorders in children ... to be the first sleep medication approved for children. ...
Breaking Medicine Technology: